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Pentraxin 3 (PTX3) is an inflammatory mediator acting as a fluid-phase pattern recog-
nition molecule and playing an essential role in innate immunity and matrix remodeling. 
Inflammatory mediators also contribute to skeletal homeostasis, operating at multiple 
levels in physiological and pathological conditions. This study was designed to investigate 
the role of PTX3 in physiological skeletal remodeling and bone healing. Micro-computed 
tomography (μCT) and bone histomorphometry of distal femur showed that PTX3 
gene-targeted female and male mice (ptx3−/−) had lower trabecular bone volume than 
their wild-type (ptx3+/+) littermates (BV/TV by μCT: 3.50 ± 1.31 vs 6.09 ± 1.17 for females, 
p < 0.0001; BV/TV 9.06 ± 1.89 vs 10.47 ± 1.97 for males, p = 0.0435). In addition, μCT 
revealed lower trabecular bone volume in second lumbar vertebra of ptx3−/− mice. PTX3 
was increasingly expressed during osteoblast maturation in vitro and was able to reverse 
the negative effect of fibroblast growth factor 2 (FGF2) on osteoblast differentiation. This 
effect was specific for the N-terminal domain of PTX3 that contains the FGF2-binding site. 
By using the closed transversal tibial fracture model, we found that ptx3−/− female mice 
formed significantly less mineralized callus during the anabolic phase following fracture 
injury compared to ptx3+/+ mice (BV/TV 17.05 ± 4.59 vs 20.47 ± 3.32, p = 0.0195). Non-
hematopoietic periosteal cells highly upregulated PTX3 expression during the initial phase 
of fracture healing, particularly CD51+ and αSma+ osteoprogenitor subsets, and callus 
tissue exhibited concomitant expression of PTX3 and FGF2 around the fracture site. 
Thus, PTX3 supports maintenance of the bone mass possibly by inhibiting FGF2 and its 
negative impact on bone formation. Moreover, PTX3 enables timely occurring sequence 
of callus mineralization after bone fracture injury. These results indicate that PTX3 plays 
an important role in bone homeostasis and in proper matrix mineralization during fracture 
repair, a reflection of the function of this molecule in tissue homeostasis and repair.
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inTrODUcTiOn
The long pentraxin 3 (PTX3) is a member of the evolutionarily conserved pentraxin superfamily, 
acting as a soluble pattern recognition molecule (1). The mature protein is a complex octameric 
molecule whose composing protomer subunits comprise a long N-terminal domain, unrelated to any 
known protein, and a C-terminal domain homologous to the classical pentraxins, C-reactive protein, 
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and serum amyloid P component (SAP), which collectively form 
the short arm of the superfamily (2). PTX3 is induced by primary 
pro-inflammatory cytokines, mainly tumor necrosis factor-α 
(TNF-α) and interleukin-1 (IL-1), and Toll-like receptor (TLR) 
agonists in different cell types, such as myeloid (i.e., mononuclear 
phagocytes, neutrophils, and dendritic cells), endothelial, and 
stromal cells (1, 3, 4).
A number of animal models and human studies have shown 
that PTX3 exerts complex non-redundant roles in the innate 
resistance to pathogens (5–7), in the regulation of inflammation 
and tissue repair (8), acting also as an oncosuppressor gene (9). 
The multifaceted biology of PTX3 likely originates from its capac-
ity to interact with a broad spectrum of ligands, including com-
plement components (C1q, factor H, C4 binding protein, ficolins, 
and mannose-binding lectin), adhesion molecules (P-selectin), 
growth factors [fibroblast growth factor 2 (FGF2) and other mem-
bers of the FGF family], and extracellular matrix components 
(inter-α-trypsin inhibitor, TNF-inducible gene-6, and fibrin), as 
well as to recognize late apoptotic cells and microbes (1, 4).
Several lines of evidence indicate that pentraxins, through 
the interplay with various hormones, growth factors, and matrix 
proteins, are involved in tissue remodeling in both physi-
ological and pathological conditions. It has been shown that 
ptx3−/− female mice display a severely impaired fertility due 
to defective assembly of the viscoelastic hyaluronic acid-rich 
matrix surrounding the oocyte in the preovulatory cumulus 
oophorus complex (10, 11). In different models of tissue dam-
age (skin wound healing, chemically induced sterile liver and 
lung injury, arterial thrombosis), PTX3 deficiency has been 
associated with increased clot formation, fibrin persistence, 
and enhanced collagen deposition (12). In this context, mac-
rophages and mesenchymal cells release PTX3 in response to 
TLR activation and IL-1 stimulation, and the secreted protein 
promotes remodeling of the fibrin-rich inflammatory matrix, 
ensuring hemostasis and efficient wound healing. This infor-
mation notwithstanding, no evidence is available regarding the 
role of PTX3 in bone turnover, an additional example of tissue 
remodeling.
Skeletal metabolism is regulated by the cooperative action 
of two major cell lineages, the mesenchymal osteoblast lineage 
that mediates bone formation and the hematopoietic osteoclast 
lineage responsible for bone resorption, with additional contribu-
tions from monocytes, macrophages, lymphocytes, and mast cells 
(13, 14). Bone remodeling is a highly coordinated process consis-
ting of timely occurring bone resorption and formation, triggered 
by changes in mechanical forces and/or microdamage and modu-
lated by a number of factors including inflammation, hormonal 
levels, and local mediators (15). At various stages of bone remod-
eling and repair, progenitor cells, osteoclasts, and osteoblasts 
com municate through multiple cell-to-cell and cell-to-matrix 
interactions via a number of signaling molecules, including tis-
sue growth factors, cytokines, and matrix proteins. Maintenance 
of skeletal homeostasis during physiological bone turnover and 
initiation of efficient reparative process after bone injury are 
crucial to preserve the major biological roles of the bone tissue, 
i.e., provide support to mechanical load and exert metabolic 
functions (16–18).
Bone remodeling is crucial to control the reshaping or replace-
ment of bone during growth and following injuries (15). Fractures 
are one of the most frequent injuries of the musculoskeletal 
system, affecting not only the bone itself but also the periosteum, 
blood vessels, and the surrounding soft tissue. Fracture heal-
ing is a sequential process that requires a complex interaction 
among molecular factors, immune cells, resident tissue cells, and 
progenitor cells to stimulate inflammation, angiogenesis, mes-
enchymal progenitor recruitment, cartilage and bone formation, 
extracellular matrix synthesis, and callus remodeling (19, 20). 
Inflammatory cells (neutrophils and macrophages) infiltrate the 
injured area, where they produce inflammatory mediators, such 
as TNF-α, IL-6, and prostaglandin E2. Mesenchymal progeni-
tors recruited to the site of injury undergo endochondral bone 
formation, initially differentiating into cartilage, which is further 
replaced by the calcified bone that incorporates the bone marrow. 
In addition, periosteal mesenchymal progenitors adjacent to the 
fracture gap differentiate directly into osteoblasts by intram-
embranous ossification. Therefore, a local acute inflammatory 
response sets within the first few days from fracture is required 
to initiate an adequate healing process (21, 22).
The aim of this study is to investigate the role of the inflamma-
tory mediator PTX3 during physiological bone remodeling and 
fracture healing. By using ptx3−/− mice, we found that PTX3 is 
important for bone tissue homeostasis and fracture repair. PTX3 
is expressed by osteoblast lineage cells, with osteoprogenitor cells 
being the major source of PTX3 in the early inflammatory stages 
of fracture healing.
MaTerials anD MeThODs
Mice
Ptx3−/− (knockout) mice, generated as previously described (6), 
were used on a 129/SvPas or C57BL/6J inbred (backcrossed for 11 
generations) genetic background. Wild-type (ptx3+/+) mice were 
obtained from Charles River (Charles River Laboratories, Calco, 
Italy) or were cohoused littermates. Femora and lumbar vertebrae 
were collected from mice housed in the specific pathogen-free 
animal facility of the Humanitas Clinical and Research Center 
in individually ventilated cages. Animals of 10–12  weeks old 
(young mice) or 6–8 months old (old mice) were used. Procedures 
involving animals handling and care were conformed to protocols 
approved by the Ethics Committees of the Humanitas Clinical and 
Research Center (Rozzano, Milan, Italy). For the in vivo fracture 
experiments, the mice were transported from Humanitas Clinical 
and Research Center and housed until 14–16 weeks old, in groups 
of three to four per cage, and maintained at standard conditions 
with food and water ad  libitum at the animal facility of the 
Croatian Institute for Brain Research, University of Zagreb School 
of Medicine (Zagreb, Croatia). All experimental procedures were 
reviewed and approved by the Ethics Committee of the University 
of Zagreb School of Medicine and conducted in accordance with 
accepted standards of humane care and use of laboratory animals. 
All procedures were performed under tribromoethanol (Avertin) 
anesthesia, and all efforts were made to minimize suffering of 
mice during experiments.
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recombinant PTX3
Recombinant human PTX3 and its C-terminal (C-PTX3) and 
N-terminal (N-PTX3) domains were purified under endotoxin-
free conditions from the supernatants of stably transfected 
Chinese hamster ovary cells as previously described (8).
Bone cell cultures
For osteoblast generation, bone marrow cells were flushed out 
from the femoral medullary cavity of ptx3+/+ or ptx3−/− mice. Cells 
adjacent to endosteal and periosteal surfaces of mid-diaphyseal 
femoral bone shafts were released by homogenization. Harvested 
cells were plated into 24-well plates at a density of 0.8 × 106 cells/
well in 0.8 mL/well of α-MEM/10% fetal calf serum (FCS). Three 
wells from two to three mice were done for each gender/genotype, 
and three independent experiments were performed. Osteoblast 
differentiation was induced from day 7 by addition of 50 µg/mL 
ascorbic acid (AA) and 8  mM β-glycerophosphate (β-GP) 
(Sigma-Aldrich for both, Saint Louis, MO, USA). At day 14–17, 
osteoblast cultures were stained cytochemically for the activity 
of alkaline phosphatase (ALP) using a commercially available 
kit (Sigma-Aldrich), and red color ALP+ osteoblast surface per 
well was measured by a custom-made software (23). Total colony 
surface was assessed by methylene blue staining.
For osteoclast generation, bone marrow cells from ptx3+/+ or 
ptx3−/− mice were cultured overnight with 5 ng/mL recombinant 
mouse M-CSF (R&D Systems, NE Minneapolis, MN, USA) in α-
MEM/10% FCS to stimulate the monocyte/macrophage lineage 
followed by harvesting of non-adherent cells as enriched hemat-
opoietic monocyte/macrophage progenitors. Non-adherent cells 
were replated into 48-well plates at a density of 0.25 × 106/well in 
0.5 mL/well of α-MEM/10% FCS supplemented with 20 ng/mL 
M-CSF and 40  ng/mL RANKL (R&D Systems). Spleen cells, 
obtained by smashing the spleen tissue between a pair of frosted 
microscope slides, were cultured in 48-well plates at a density of 
0.5 × 106/well in 0.5 mL/well of α-MEM/10% FCS supplemented 
with 20 ng/mL M-CSF and 40 ng/mL RANKL. At day 5–9 of culture, 
tartrate-resistant acid phosphatase (TRAP)+ multinucleated cells 
(≥3 nuclei/cell) were identified using a commercially available 
kit (Sigma-Aldrich) and counted by light microscopy (24). Four 
wells from two to three mice were done for each gender/genotype, 
and three independent experiments were performed.
Osteoblastogenic and osteoclastogenic cultures were treated 
with a dose range of PTX3 (0–50 nM). In some experiments, either 
full-length PTX3, its N- or C-terminal domain (50 nM for all), or/
and FGF2 (0.25 nM and 0.5 nM) were added to osteoblastogenic 
cultures in addition to AA and β-GP. Molarity was expressed 
based on the molecular weight of the protomer subunits of PTX3 
and its N- and C-terminal domains, and the primary sequence 
of FGF2, that is, 42.500 kDa for PTX3, 18.163 kDa for N-PTX3, 
25.000 kDa for C-PTX3, and 17.254 kDa for FGF2 (25).
Flow cytometry
For flow cytometric analysis, bone marrow and spleen cells were 
harvested as described previously in Ref. (24). Erythrocytes 
were lysed with red blood cell lysing buffer (Sigma-Aldrich), 
and single-cell suspensions were obtained by filtering through a 
100-µm Nytex mesh. Cells were counted in a hemocytometer by 
trypan blue exclusion and labeled using a mix of commercially 
available monoclonal antibodies against hematopoietic/endothe-
lial markers (anti-CD45 APC, clone 30-F11; anti-Ter119 APC, 
clone TER-119; anti CD31 APC, clone 390), lymphoid lineage 
markers (anti-CD3 FITC, clone 145-2C11; anti-B220 FITC or 
PE-Cy7, clone RA3-6B2; anti-NK1.1 FITC or APC; clone PK136), 
myeloid lineage markers (anti-CD11b APC-eFluor 780, clone 
M1/70; anti-Ly6C APC, clone HK1.4; anti-Ly6G PerCP-eFluor 
710, clone 1A8), osteoclast progenitor markers (anti-CD115/cFms 
biotinylated, clone AFS98; anti-CD117/cKit APC, clone 2B8), 
and osteoblast progenitor markers (anti-CD166/ALCAM PE, 
clone eBioALC48; anti-Sca-1 FITC, clone D7), all from eBio-
sciences (San Diego, CA, USA). Suspensions were incubated on 
ice for 40 min, followed by washing in staining medium [2% FCS 
in phosphate-buffered saline (PBS)]. As a second step (for biot-
inylated anti-CD115), cells were stained with streptavidin coupled 
to PE-Cy7 on ice for 40  min. Finally, cells were resuspended in 
staining medium containing 0.25  μg/tube 7-aminoactinomycin 
D or 4’,6-diamidino-2-phenylindole for dead cell exclusion. 
Gates were defined using unlabeled cells, cells labeled by isotype 
controls, and fluorescence minus one controls. Samples were 
acquired using Attune (Life Technologies, ABI, Carlsbad, CA, USA) 
or BD FACSAria I (BD Biosciences, San Jose, CA, USA) instrument 
and analyzed by FlowJo software (TreeStar, Ashland, OR, USA).
Fluorescence-activated cell sorting (FACS) of osteoprogenitor 
cells was performed in a BD FACSAria I instrument. Cells were 
extracted from the periosteal layer and callus tissue and labeled 
as described previously (24). Briefly, tibias were dissected, soft 
tissue was removed, and bone marrow was flushed. Periosteal 
layer of diaphyseal bone fragments/fracture callus were briefly 
crushed using tissue homogenizer and further digested in PBS 
containing 0.1% collagenase A (Roche, Mannheim, Germany) 
for 30 min at 37°C with agitation. For phenotyping of osteoblast 
lineage cells, the following antibodies were used: anti-CD51 bioti-
nylated (clone RMV-7; with streptavidin coupled to PE-Cy7), 
anti-CD105 PE or PE-Cy7 (clone MJ7/18), anti-CD140b APC 
(clone APB5), anti-α-smooth muscle actin (αSma) Alexa Fluor 
488 (clone 1A4), and anti-Sca-1 FITC or Pacific Blue (clone D7), 
according to previous studies (26). Samples were acquired at a 
speed of approximately 3,000 cells/s to separate hematopoietic/
endothelial-negative (CD45−Ter119−CD31−) and hematopoietic-
positive fractions (CD45+Ter119+CD31+). Sorting parameters 
and experimental set-up were optimized for high purity sorting. 
Sorting purity was determined by a reanalysis of fractioned 
populations and was greater than 98% for all samples.
For flow cytometric analysis of PTX3 expression, purified goat 
immunoglobulin G (IgG) anti-mouse PTX3 (R&D Systems) or 
purified IgG from pre-immune goat serum (Agilent-Dako, Santa 
Clara, CA, USA) were used with anti-goat antibody coupled to 
PE (eBiosciences) as previously described (9). Cells were first 
stained for surface marker expression using the previously 
described antibodies to hematopoietic and osteoprogenitor 
lineages, then permeabilized with BD Cytofix/Cytoperm kit (BD 
Bio sciences), according with manufacturer’s instructions, and, 
finally, stained for intracellular expression of PTX3. Gates were 
defined using unlabeled cells and isotype controls. Specificity 
4Grc ̌ević et al. PTX3 in Bone Homeostasis and Repair
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 417
of anti-PTX3 labeling was also confirmed by parallel staining 
in ptx3+/+ and ptx3−/− mice. Samples were acquired using BD 
FACSAria I instrument and analyzed by FlowJo software.
Fractures
Closed transverse diaphyseal fractures of tibias were created in 
14- to 16-week-old female ptx3+/+ and ptx3−/− mice. Anesthesia 
was induced and maintained using tribromoethanol (Avertin), 
and 0.08 mg/kg buprenorphine hydrochloride was administered 
subcutaneously for analgesia. Prior to fracture, a tract was cre-
ated through the tibial plateau into the medullary canal using 
a 25-gauge needle, through which a 0.4-mm diameter stainless 
steel pin was positioned to fix the subsequent fracture (26). 
Fractures were created 1–2 mm proximal to the distal tibia-fibula 
junction using the modified, limited displacement three-point 
contact device (27). Unfractured bones and bones with inserted 
pins without fracture were used as controls.
Micro-computed Tomography
The distal metaphyses of femora and second lumbar vertebrae 
were scanned using a micro-computed tomography (μCT) 
system (1172 SkyScan, SkyScan, Kontich, Belgium) at 50  kV 
and 200 mA with a 0.5 aluminum filter using a detection pixel 
size of 4.3 µm (24). Images were captured every 0.7° through 
180° [second lumbar (L2) vertebrae] and every 0.7° through 
360° (femora) rotation. The scanned images were reconstructed 
using the SkyScan Recon software and analyzed using SkyScan 
CTAnalyser. Three-dimensional analysis and reconstruction of 
trabecular bone were performed on the bone region 1–2.3 mm 
distal to the growth plate. The trabecular bone compartment 
was manually delineated from the cortical bone, and the fol-
lowing parameters were measured: trabecular bone volume 
fraction (BV/TV, %), trabecular number (Tb.N/μm), trabecular 
thickness (Tb.Th; μm), and trabecular separation (Tb.Sp; μm). 
In fracture experiments, tibial fractured areas were scanned and 
three-dimensional reconstructions were performed to measure 
mineralized callus bone volume (BV/TV, %).
histology and histomorphometry
Femora were fixed in 4% paraformaldehyde, demineralized in 
14% ethylenediaminetetraacetic acid in 3% formaldehyde, dehy-
drated in increasing ethanol concentrations, and embedded in 
paraffin (24). Six-micrometer sections were cut with a Leica SM 
2000 R rotational microtome (Lieca SM 2000 R, Leica Biosystems, 
Nussloch, Germany) and stained with Goldner–Masson tri-
chrome (GT) or TRAP activity. Histomorphometric analysis was 
performed under Axio Imager microscope (Carl Zeiss) using the 
OsteoMeasure software (Osteo-Metrics, Decatur, USA).
For static histomorphometry, metaphyseal regions of GT- 
stained femora, 1  mm distally from the epiphyseal plate, were 
analyzed under 5×  objective magnification. The analyzed vari-
ables included trabecular volume (BV/TV), trabecular thick ness 
(Tb.Th, μm), trabecular number (Tb.N/μm), and trabecular 
separation (Tb.Sp, μm). On TRAP-stained sections, osteoclasts 
were identified as multinucleated cells placed adjacent to the 
bone surface. For dynamic histomorphometry, mice were 
injected twice with calcein, 20 mg/kg each, at day 7 and 2 prior 
to sacrifice. Seven-micrometer sections of undecalcified femora 
were cut using Leica cryostat and analyzed under a fluorescent 
microscope (Axio Imager, Carl Zeiss); mineral apposition rate 
(μm/day or %/day) and bone formation rate (BFR; μm3/μm2/day) 
were automatically calculated.
immunohistochemistry
Bone sections were prepared as described and deparaffinized. 
Fractured bones had the intramedullary pin removed prior to 
embedding. Sections were incubated overnight at 65°C with 
10 mM sodium citrate (pH 6) for antigen retrieval. Endogenous 
peroxidases were inactivated with 0.03% H2O2 in methanol for 
30 min at room temperature. Serial sections were blocked with 
Rodent block M (Bio care Medical, Concord, CA, USA) for PTX3, 
osterix (Osx), and runt-related transcription factor 2 (Runx2) 
staining or 5% BSA in 0.5% Triton/PBS for FGF2 staining and 
then incubated with the primary antibody at 4°C overnight. As 
primary antibodies, we used an affinity purified rabbit IgG against 
human PTX3 (5 µg/mL), a monoclonal rabbit IgG against mouse/
rat/human Osx (1:1,000; Abcam, Cambridge, UK), a monoclonal 
rabbit IgG against mouse/rat/human Runx2 (1:2,000; Abcam), 
or polyclonal goat IgG against human FGF2 (5  µg/mL; R&D 
Systems) (28). Secondary reagents were Envision anti-rabbit horse 
radish peroxidase (HRP) (Dako, Glostrup, Denmark) for PTX3, 
Osx, and Runx2 staining or goat probe with goat HRP polymer 
(Bio care Medical) for FGF2 staining. Reactions were visualized 
using 3.3′-diaminobenzidine as a chromogen (Vector laboratories 
Inc. Burlingham, CA, USA) and stopped with distilled water. 
Sections were counterstained with hematoxylin and covered using 
Hydromount (National Diagnostics, Atlanta, GA, USA).
For quantitative analysis of PTX3 expression, images of three 
serial sections from four mice per group were digitally captured at 
200× magnification. PTX3 immunoreactive areas were measured 
using ImageJ software (version 1.45; NIH, MD, USA). Immuno-
reactive area was automatically selected on the basis of immuno-
reactive sample intensity, and results are expressed as median 
percentage of the immunoreactive pixels in total pixels with 
interquartile range (IQR).
gene expression analysis
Total RNA from cultures and callus-derived cells was extracted 
using TRIzol Reagent (Applied Biosystems, Thermo Fisher Scien-
tific, Waltham, MA, USA), reversely transcribed (1 µg) to cDNA, 
and amplified (20 ng/well in duplicates) by quantitative (q)PCR 
using an AB7500 (Applied Biosystems) instrument. Each sample 
was prepared by pooling three to four culture wells or callus 
tissue from two to three bones. RNA quality was verified on a 
Bioanalyzer RNA PicoChip (Agilent Technologies, Santa Clara, 
CA, USA) and quantified using Nanodrop spectrophotometer 
(Thermo Scientific, Thermo Fisher Scientific). Expression of 
osteoblast-specific genes: osteocalcin (OC), bone sialoprotein 
(BSP), Osx, ALP, α2-chain of type I collagen (Col1); osteoclast 
specific genes: colony stimulating factor 1 receptor (cFms), recep-
tor activator of nuclear factor-κB (RANK), and calcitonin recep-
tor (CalcR); inflammatory markers: C-C chemokine ligand 2 
(CCL2), TNF-α, IL-1α, and IL-6; and regulatory molecules: PTX3 
and FGF2 was determined using commercially available TaqMan 
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Gene Expression Assays (Applied Biosystems). The expression of 
a specific gene was calculated according to the relative standard 
curve of gene expression in the calibrator sample (cDNA from 
ptx3+/+ callus or cultures) and then normalized to the expression 
level of the β-actin gene as an endogenous control (24).
elisa
Blood was collected from the retro-orbital plexus of control and 
fractured mice at day 2 and 6 postfracture; serum was stored at 
−20°C until cytokine analysis. Murine PTX3, CCL2, TNF-α, and 
IL-6 levels were measured in serum by ELISA (DuoSet ELISA 
Development System, R&D Systems) according to manufacturer’s 
instructions.
statistics
Normality of data distribution was verified using Kolmogorov–
Smirnov test. Number of independent experiments performed 
for each setting with total number of analyzed mice per group is 
indicated in figure legends. Results are presented as mean ± SD 
for normally distributed data or median with IQR for not-
normally distributed data. Statistical analysis of the group dif-
ference was performed using the parametric Student’s t-test 
(for group-to-group comparison) and analysis of variance with 
Student–Newman–Keuls post hoc test (for multiple group com-
parisons) or the non-parametric Kruskal–Wallis test followed by 
Mann–Whitney test. For all experiments, α-level was set at 0.05. 
Statistical analysis was performed using the software packages 
MedCalc (version 12.5, MedCalc Inc., Mariakerke, Belgium).
resUlTs
Ptx3−/− Female Mice have lower Bone 
Mass compared to ptx3+/+ Mice
In the first set of experiments, we aimed to investigate the role 
of PTX3 in maintenance of skeletal homeostasis. Both axial 
(at the level of L2 vertebra) and appendicular (at the level of distal 
femoral metaphysis) skeleton of ptx3+/+and ptx3−/− mice were 
assessed by μCT. Distal femora from young adult ptx3−/−females 
(10–12 weeks old) on B6 background showed highly significant 
decrease in trabecular bone volume (p < 0.0001), which was par-
alleled by decreased trabecular number and trabecular thickness, 
as well as increased trabecular separation compared to ptx3+/+ 
mice (Figure  1). Difference in distal femoral trabecular bone 
volume was marginally significant between ptx3−/− and ptx3+/+ 
males (p = 0.0435), with lower trabecular number in ptx3−/−mice. 
Moreover, trabecular bone volume, trabecular number, and 
trabecular thickness were decreased in lumbar vertebrae from 
ptx3−/− compared to ptx3+/+ female and male mice (Figure  1). 
Histomorphometry of distal femoral histological sections con-
firmed lower bone mass in ptx3−/− female and male mice found 
by μCT (Figure S1 in Supplementary Material). Finally, we ana-
lyzed bone mass in aged female ptx3−/− mice (6–8 months old) 
on B6 background and found significantly lower distal femoral 
trabecular bone volume and trabecular thickness compared to 
ptx3+/+ mice (Figure S2 in Supplementary Material).
In addition, μCT analysis performed in young adult mice on 
S129 background revealed the decrease in trabecular bone volume 
in distal femora of both female and male ptx3−/−mice as well as 
in axial skeleton of ptx3−/− females (Figure S3 in Supplementary 
Material). These findings point to strain-independent alteration 
in bone remodeling, in particular in female mice lacking the 
PTX3 gene.
PTX3 Deficiency Does not affect the 
Osteoclastogenic and Osteoblastogenic 
Potential of Progenitor cells In Vitro
To clarify the mechanisms underlying the bone phenotype 
in ptx3−/− mice, we analyzed the osteoclastogenic and osteoblasto-
genic potential of bone progenitor cells. Osteoclasts were differ-
entiated from bone marrow and spleen cells in the presence 
of  RANKL and M-CSF. Number of differentiated osteoclasts, 
detected as TRAP+ multinucleated cells, did not significantly 
differ between ptx3+/+ and ptx3−/− mice in both females and 
males (Figure 2A). In addition, frequency of putative osteoclast 
progenitors (29, 30), defined as CD3−B220−CD11b−/locKit+cFms+ 
subset for bone marrow (Figure S4A in Supplementary Material) 
and CD3−B220−NK1.1−CD11b+Ly6C+cFms+ subset for spleen 
(not shown), was comparable between ptx3+/+ and ptx3−/− mice.
Osteoblasts were differentiated in  vitro from bone marrow 
and bone adjacent (endosteal and periosteal) cells by the addi-
tion of AA and β-GP. Ptx3−/− mice did not show significant 
difference in the percentage of ALP+ surface area (Figure  2B) 
as well as frequency of osteoprogenitor cells (31, 32), defined as 
CD45−Ter119−CD31−CD166+Sca-1+ subset (Figure S4B in Supple-
mentary Material for bone marrow; not shown for bone adjacent 
cells). Our findings indicated that osteoclast and osteoblast 
progenitors retain similar differentiation potential in the absence 
of PTX3 in  vitro and prompted us to focus on the functional 
properties of bone cells in vivo.
Ptx3−/− Mice have reduced In Vivo 
Functional activity of Osteoblast  
lineage cells
Since reduction in bone mass arises from unbalanced bone 
resorption (by osteoclasts) and formation (by osteoblasts), we asses-
sed in  vivo activity of osteoclasts and osteoblasts on histology 
specimens from distal femora. Ptx3−/− mice did not differ from 
ptx3+/+ mice in the number of active trabecular and endosteal 
osteoclasts, counted as multinucleated TRAP+ cells adjacent to 
the bone surface (Figure 3A). However, dynamic histomorpho-
metry, measuring distance of calcein labels injected in 5-day 
interval, revealed defective osteoblast activity and decreased BFR 
on endosteal and trabecular bone surface in both female and male 
ptx3−/− mice (Figure 3B). These findings suggest that the lower 
bone volume in ptx3−/− mice might be ascribed to suppressed 
osteoblast function and prompted us to exploit functional model 
of bone injury requiring intensive new bone formation in vivo.
Ptx3−/− Mice have reduced callus 
Mineralized Volume during  
Fracture healing
A tibia mid-diaphyseal fracture model allowed assessment of 
the capacity of new bone formation and bone regeneration in 
FigUre 1 | Bone phenotype of the axial and appendicular skeleton in young adult ptx3+/+ and ptx3−/− mice. Female and male ptx3+/+ and ptx3−/− mice  
(10–12 weeks of age) were sacrificed, and the second lumbar vertebrae and distal femora were analyzed for trabecular bone parameters by micro-computed 
tomography (μCT). (a) Representative images of three-dimensional reconstruction of selected areas of the distal femur (left panel) and second lumbar vertebra  
(right panel). (B) Quantitative μCT analysis of trabecular bone volume (BV/TV, bone volume/total volume), trabecular number (Tb.N), trabecular thickness (Tb.Th),  
and trabecular separation (Tb.Sp) in the distal femoral metaphysis (left panel) and second lumbar vertebra (right panel). Cumulative data from three independent  
sets of experiments are shown (n = 18–20 mice per group). Dots represent individual mice, and horizontal lines and error bars are mean ± SD; statistically  
significant difference between corresponding ptx3+/+and ptx3−/− groups is marked on plots (*p < 0.05, **p < 0.001; unpaired Student’s t-test); ns, not significant.
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ptx3−/− mice. Three weeks after tibial fracture injury, during 
the reparative phase of the fracture healing process marked 
by intensive endochondral and intramembranous ossification, 
both percentage of mineralized callus tissue and expression of 
the bone-specific marker Col1 were lower in female ptx3−/−mice 
than in ptx3+/+ controls (Figures 4A,B). Immunohistochemistry 
revealed that PTX3 is present in the callus tissue of ptx3+/+ mice 
during the mineralizing phase of fracture healing (Figure 4C). 
Areas of newly formed mineralized tissue (detected as GT green 
stain) produce PTX3, including cuboidal active osteoblasts, 
mostly apparent on high magnification. Therefore, we concluded 
that PTX3 has a role during fracture repair and that inactivation 
of the PTX3 gene is responsible for the reduced osteoblast func-
tion and incomplete bone formation observed in ptx3−/− mice.
PTX3 is expressed during the early 
inflammatory Phase of Bone healing
Pentraxin 3 has been implicated in a number of inflamma-
tory conditions (33); therefore, we further examined the time 
course of PTX3 expression during the early inflammatory phase 
of fracture healing in ptx3+/+ mice. Immunohistochemistry 
FigUre 2 | In vitro osteoclastogenic and osteoblastogenic potential of ptx3+/+ and ptx3−/− mice. Bone marrow (BM) and spleen (SPL) cells were extracted from 
ptx3+/+ and ptx3−/− female and male mice (10–12 weeks of age) and plated in osteoclastogenic cultures (in the presence of RANKL and M-CSF), or BM and 
bone-associated cells (BACs) were plated in osteoblastogenic cultures [in the presence of ascorbic acid (AA) and β-GP]. Cells from two to three mice were pooled;  
four wells for osteoclasts and three wells for osteoblasts were done for each gender/genotype; three independent sets of experiments were performed.  
(a) Representative microphotographs of osteoclasts differentiated in vitro from the BM of ptx3+/+ and ptx3−/− mice, cytochemically stained for tartrate-resistant  
acid phosphatase (TRAP) activity (left panel). TRAP+ cells with three or more nuclei in cultures of BM and spleen from ptx3+/+ and ptx3−/− female and male  
mice were counted, and results are expressed as number of TRAP+ cells/well (right panel). (B) Representative microphotographs of osteoblasts differentiated  
in vitro from BM of ptx3+/+ and ptx3−/− mice, cytochemically stained for alkaline phosphatase (ALP) activity (left panel). ALP+ surface area in cultures of BM and BACs 
from ptx3+/+ and ptx3−/− female and male mice were measured, and results are expressed as percentage of ALP+ surface/well (right panel). Data from all performed 
experiments are shown (n = 12 wells per group for osteoclasts; n = 9 wells per group for osteoblasts). Each dot represents values from one culture well; horizontal 
lines and error bars are mean ± SD; no statistically significant difference between corresponding ptx3+/+and ptx3−/− groups was observed (unpaired Student’s t-test).
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revealed weakly positive osteocytes incorporated in the cortical 
bone matrix even in the unfractured bone tissue (Figure 5A). 
Moreover, expression of PTX3 is induced in the soft callus 
tissue early after the bone fracture injury, as evidenced by the 
significant increase of immunopositive area at day 6 postfrac-
ture (median, 5.3; IQR, 3.6–9.4 vs 0.4, IQR, 0.2–0.6 in control; 
p = 0.0012) (Figure 5A). Specifically, in areas of endochondral 
ossification, hypertrophying chondrocytes highly express PTX3 
(Figure 5B). In parallel, serum level of PTX3 was increased at 
day 2 postfracture compared to unfractured ptx3+/+ mice (Figure 
S5A in Supplementary Material).
Furthermore, we tested whether mice lacking the inflam-
matory mediator PTX3 show alterations in systemic and local 
fracture-induced inflammatory response at early postfracture 
days. Serum levels of the inflammatory chemokine CCL2 were 
comparable between ptx3+/+ and ptx3−/− mice, with the peak 
value at day 2 postfracture (Figure S5A in Supplementary 
Material). Levels of TNF-α and IL-6 were undetectable in serum 
FigUre 3 |  In vivo osteoclast and osteoblast activity in ptx3+/+ and ptx3−/− mice. Sections of distal femoral metaphysis from ptx3+/+ and ptx3−/− female and male mice 
(10–12 weeks of age) were histochemically stained for tartrate-resistant acid phosphatase (TRAP) activity. Goldner–Masson trichrome (GT) staining was used to 
visualize mineralized matrix (green) in serial sections of cortical and trabecular (TRB) compartments (size bar: 100 µm). Calcein (CALC) interlabel distance in distal 
femoral metaphysis from ptx3+/+ and ptx3−/− female and male mice were measured to estimate the rate of bone formation. (a) Representative microphotographs of 
active TRAP+ osteoclasts (OCL) adjacent to edosteal (END) and TRB bone surfaces (indicated by arrowheads) in ptx3+/+ mice (not shown for ptx3−/− mice). 
Quantification of END and TRB TRAP+ osteoclasts per bone perimeter (N.Oc./B.Pm) in ptx3+/+ and ptx3−/− female and male mice (n = 6–8 mice per group) is reported 
below. (B) Representative microphotographs of distal femoral metaphyseal sections from mice injected with calcein; interlabel distance visualized by fluorescent 
microscopy (indicated by arrowheads). Histomorphometric evaluation of endosteal bone formation rate (BFR) relative to bone surface area (BFR/BS) and TRB BFR 
relative to bone volume (BFR/BV) in ptx3+/+ and ptx3−/− female and male mice (n = 6–8 mice per group) is reported below. Dots represent individual mice, and horizontal 
lines and error bars are mean ± SD; statistically significant difference between corresponding ptx3+/+and ptx3−/− groups is marked on plots (*p < 0.05; unpaired 
Student’s t-test).
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FigUre 4 | Evaluation of fracture callus tissue at 3 weeks postfracture in ptx3+/+ and ptx3−/− female mice. Stabilized closed transversal mid-tibial fracture model  
was applied in female ptx3+/+(n = 16) and ptx3−/− (n = 18) mice on B6 background (14–16 weeks of age). Assessment of callus tissue at 3 weeks postfracture was 
performed by micro-computed tomography (μCT) analysis, qPCR, and histology. (a) Representative microphotographs of three-dimensional reconstruction of tibial 
fractured areas and callus tissue sections of ptx3+/+ and ptx3−/− mice assessed by μCT. (B) Quantitative μCT analysis of mineralized callus bone volume (BV/TV, bone 
volume/total volume) of ptx3+/+ and ptx3−/− mice. Dots represent individual mice, and horizontal lines and error bars are mean ± SD (upper panel). qPCR assessment 
of bone-specific α2-chain of type I collagen (Col1) expression in ptx3+/+ and ptx3−/− mice. Values (n = 5 per group) are presented as mean ± SD (lower panel). 
Statistically significant difference between corresponding ptx3+/+and ptx3−/− groups is marked on plots (*p < 0.05; unpaired Student’s t-test). (c) Sections of 
mid-tibial callus area (indicated by arrow on μCT microphotograph) from ptx3+/+ and ptx3−/− female mice were stained immunohistochemically with an anti-PTX3 
antibody. Goldner–Masson trichrome (GT) staining was used to visualize mineralized matrix (green) in callus compartment (size bar: 100 µm). In the selected area, 
PTX3+ cuboidal osteoblasts present during the anabolic stage of fracture healing are indicated by arrowheads.
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FigUre 5 | Pentraxin 3 (PTX3) expression within the fractured areas at early postfracture days in ptx3+/+ female mice. A stabilized closed transversal mid-tibial 
fracture model was applied in female ptx3+/+ (n = 18) mice (14–16 weeks of age). Callus tissue was assessed at 2 (FRd2) and 6 (FRd6) days postfracture (indicated 
by arrow on micro-computed tomography). (a) Sections of mid-tibial unfractured bone (UNFR) and fracture area (FRd2 and FRd6) from ptx3+/+ female mice were 
stained immunohistochemically with an anti-PTX3 antibody. Numbers indicate median percentage of immunopositive area (immunopositive pixels/total pixels) with 
interquartile range analyzed by ImageJ software (n = 4 slides per group); statistically significant difference was observed for FRd6 compared to other groups 
(*p < 0.05; Kruskal–Wallis with Mann–Whitney post hoc test). Control (ctrl) stain was performed using the secondary antibody only. Goldner–Masson trichrome (GT) 
staining was used to visualize fractured site in mineralized bone cortex (green) (size bar: 100 µm). Selected areas are presented in higher magnification to better 
visualize PTX+ cells (indicated by arrowheads). (B) Representative microphotographs of the fractured areas with intensive endochondral ossification at day 6 
postfracture. In the selected area, numerous hypertrophic PTX3+ chondrocytes are present during fracture healing.
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of both ptx3+/+ and ptx3−/− mice (data not shown). Analysis of 
periosteal/callus tissue associated with fracture site revealed that 
an increase in CCL2 expression and accumulation of myeloid 
cell subpopulations (Ly6C+, Ly6G+) was associated with frac-
ture injury (Figures S5B,C in Supplementary Material). At the 
selected time points of 2 and 6 days postfracture, neither TNF-α 
nor IL-1α showed significant changes at the gene expression 
level (Figure S5B in Supplementary Material), possibly because 
their increase occurs much earlier following injury. However, 
no obvious differences were observed in the expression of 
pro-inflammatory cytokines (CCL2 and IL-1α, Figure S5B in 
Supplementary Material; IL-6, not shown) or the frequency of 
inflammatory cell subsets (Ly6C+, Ly6G+, and CD11b+) between 
ptx3+/+ and ptx3−/− mice (Figure S5C in Supplementary Material).
The fracture model used is based on the intramedullary inser-
tion of a stainless steel pin that, per se, can induce an inflam ma tory 
response. Thus, we assessed in both ptx3+/+ and ptx3−/− mice the 
contribution of injury made by the intramedullary pin insertion 
to the inflammatory response associated with the fracture model 
applied in this set of experiments. Expression of inflammatory 
mediators did not significantly differ between control (intact) 
animals and animals with inserted pins. Although pin insertion 
probably causes a certain level of intramedullary inflammatory 
response, bone injury and subsequent periosteal reaction seem 
to be necessary to produce increased expression of inflammatory 
markers in serum and callus tissue (Figure S5 in Supplementary 
Material).
Flow cytometry analysis of the callus cellular components 
showed that the percentage of non-hematopoietic/non-endothelial 
cells extracted from the callus tissue increased at early times from 
fracture (day 2 and 6). Expression of the PTX3 gene was strongly 
and selectively induced in non-hematopoietic/non-endothelial 
CD45−Ter119−CD31− population (Figure 6A). The presence of 
active osteoprogenitor cells in the callus was confirmed by high 
FigUre 6 | Callus composition at early postfracture days in ptx3+/+ female mice. Stabilized closed transversal mid-tibial fracture model was applied in female ptx3+/+ 
mice (14–16 weeks of age). Assessment of callus tissue at 2 (FRd2) and 6 (FRd6) days postfracture was performed by flow cytometry and qPCR. Flow cytometric 
analysis and cell sorting of hematopoietic (CD45+Ter119+CD31+) and non-hematopoietic/non-endothelial (CD45−Ter119−CD31−) subsets of callus cells were 
performed in unfractured tibial periosteal layer (UNFR) and fractured areas involving periosteal reaction (FRd2 and FRd6). (a) Percentage of hematopoietic (Hem+) 
and non-hematopoietic/non-endothelial (Hem−) cells in callus tissue (left panel). qPCR analysis of PTX3 gene expression in total callus cell population and 
non-hematopoietic/non-endothelial (Hem−) compartment of extracted cells (right panel). A total number of 12–16 mice per group were analyzed in 4 independent 
experiments. Values are shown as mean ± SD; statistically significant difference between corresponding total and Hem− groups is marked on plots (*p < 0.001; 
unpaired Student’s t-test). (B) Hematopoietic compartment (CD45+Ter119+CD31+ subset) and non-hematopoietic/non-endothelial compartment (CD45−Ter119−
CD31− subset) were separately analyzed for the expression of hematopoietic lineage markers (Ly6G, Ly6C, CD11b, B220, CD3) and osteoprogenitor cell markers 
(CD51, CD140b, CD105, αSma, Sca-1), respectively. (c) Expression of osteoblast-specific genes (Osx, ALP, BSP, Col1, OC) were assessed at early postfracture 
days in total callus tissue by qPCR and expressed as relative quantity compared to periosteal samples of unfractured bones (n = 4 per group). ALP, alkaline 
phosphatase; BSP, bone sialoprotein; Col1, α2-chain of type I collagen; OC, osteocalcin; Osx, osterix; PTX3, pentraxin 3; αSma, α-smooth muscle actin.
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levels of expression of several bone-specific genes (Osx, ALP, BSP, 
and Col1). Non-hematopoietic subset accounted for ~20% of the 
callus cell population and expressed osteoprogenitor markers, 
including CD51, CD140b, and, to a lesser extent, CD105 and αSma 
(Figures  6B,C). The hematopoietic subset (CD45+Ter119+CD31+) 
comprised multiple cell lineages, mostly myeloid cells (Ly6C+, 
Ly6G+ and CD11b+) and some lymphoid cells (CD3+ and B220+; 
NK1.1+, data not shown). Nevertheless, the expression of PTX3 
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appears to be confined to the non-hematopoietic compartment, 
as no PTX3 mRNA could be detected in the hematopoietic subset 
at the analyzed time points (data not shown).
PTX3 expression increases with Bone cell 
Differentiation In Vitro
Next, we asked whether PTX3 could act as an autocrine 
growth factor for bone cells and characterized the kinetics of 
PTX3 expression (along with that of selected differentiation-
specific genes) in osteoclastogenic and osteoblastogenic cultures 
(Figure  7A). Osteoblast differentiation (as induced by AA and 
β-GP) was confirmed by a large increase in the expression of both 
early and late osteoblast-specific genes (Osx, ALP, OC). In these 
conditions, PTX3 expression was highly induced at later time 
points. Osteoclastogenic cultures derived from bone marrow cells 
and stimulated with RANKL and M-CSF showed an increased 
expression of differentiation genes (cFms, RANK, and CalcR). 
PTX3 was also expressed in the course of osteoclast maturation, 
however, at lower levels (6- to 10-fold less) than those observed 
in the osteoblastogenic cultures (PTX3 was normalized using 
the same relative standard curve to allow comparison of the two 
cultures).
Although we observed a marked increase in PTX3 expression 
in mature osteoblasts in  vitro and could expect, from previous 
findings, that PTX3 may directly stimulate osteoblast maturation, 
exogenously added PTX3 did not change the percentage of sur-
face covered by ALP+ osteoblast (Figure S6A in Supplementary 
Material). Similarly, addition of PTX3 into osteoclastogenic cul-
tures did not alter the number of mature TRAP+ multinucleated 
osteoclasts. Therefore, we proposed that PTX3 action on bone 
cells may be indirect, through interaction with some other bone 
matrix regulatory protein.
PTX3 Binds to FgF2 and reverses its 
inhibitory role in Osteoblast 
Differentiation
To elucidate the mechanisms by which PTX3 is required for 
physiological bone formation and bone tissue regeneration 
after injury, we performed combined treatment of osteoblasto-
genic cultures with PTX3 and FGF2, a known regulator of 
osteoblastogenesis and also a ligand of PTX3 (34). As shown in 
Figures 7B,C, addition of FGF2 markedly reduced the percentage 
of surface covered by ALP+ osteoblast after culture treatment in a 
dose-dependent manner. This effect is only seen if FGF2 is added 
during the differentiation phase (day 7–14) of osteoblastogenic 
cultures and not during the proliferative phase (day 0–7), as 
described in Materials and Methods (Figure S6B in Supplementary 
Material). Addition of PTX3 to FGF2 treatment was able to 
reverse the negative effect of FGF2 on osteoblast differentiation 
(Figures 7B,C). The N-terminal domain of PTX3 [that contains 
the FGF2-binding site (35)] recapitulates the FGF2-neutralizing 
activity of the full lengths protein, whereas no effect was observed 
with the C-terminal domain (that does not interact with FGF2). 
In addition, FGF2 strongly suppressed the expression of the dif-
ferentiation markers Osx, Col1, and BSP, whereas PTX3 rescued 
their expression toward control levels (Figure 7D).
Finally, FGF2 was detected (both protein and mRNA) at early 
days from fracture and showed a similar pattern of expression as 
PTX3 in bone sections and extracted callus cells of ptx3+/+ mice 
(Figures  8A,D). Moreover, immunohistochemical staining of 
serial bone sections indicated concomitant high expression of 
Osx and Runx2 by infiltrating osteoprogenitor cells in the areas 
of periosteal reaction and bone induction (Figure 8A). The cel-
lular source of PTX3 was determined by intracellular staining 
of PTX3 in parallel to the staining of surface hematopoietic 
(data not shown) and mesenchymal/osteoprogenitor markers 
using flow cytometry (Figures 8B,C). The percentage of PTX3+ 
cells increased following fracture (Figure 8B), and among them, 
the most abundant subsets were αSma+ early osteoprogenitors 
and CD51+ more mature preosteoblast (Figure  8C), whereas 
hematopoietic cells exhibited almost no PTX3 expression at 
day 2 and 6 postfracture (data not shown). There were no dif-
ferences in PTX3 expression between control (intact) animals 
and animals with inserted pins (Figure  8B). A similar pattern 
of expression for FGF2, Osx, and Runx2 was observed in bone 
sections of ptx3−/− mice, with no PTX3 immunoreactivity 
(Figure S7 in Supplementary Material). In addition, the percent-
ages of hematopoietic/endothelial-negative (CD45−Ter119− 
CD31−) osteo progenitor subpopulations (CD51+ and CD140b+, 
Figure S8 in Supplementary Material; CD105, data not shown) 
were comparable between ptx3+/+ and ptx3−/− mice except for 
the αSma+ subset that was lower in ptx3−/− mice (Figure S8 in 
Supplementary Material).
On the basis of these findings we propose that PTX3, pro-
duced by osteoblast lineage cells, serves as a bone protective fac-
tor, important to unlock osteoblast maturation by neutralizing 
the FGF2 anti-differentiation effect during bone formation.
DiscUssiOn
In this study, we identified a new role for the long pentraxin 
PTX3 as a local regulator of bone metabolism. We observed 
that young adult ptx3−/−mice (2.5  months of age) have lower 
trabecular bone mass in long bones and axial skeleton, indicat-
ing that genetic deficiency of PTX3 alters the balance between 
bone formation and resorption in both B6 and S129 strain. 
Skeletal sexual dimorphism is present in ptx3−/− mice, since 
more obvious bone phenotype compared to ptx3+/+ mice has 
been observed for young adult females, known to have lower 
BFR compared to male mice at the analyzed age (36). Levels 
of several hormones, cytokines, and growth factors important 
for osteoblast function may be different in females vs males 
(including sex hormones, growth hormone, and RANKL), 
making them susceptible to specific conditions, i.e., PTX3 
deficiency (37). Compared to 2.5 months, the bone phenotype 
was less pronounced in females at 6–8 months when age-related 
decline in osteoblast functions and trabecular bone loss have 
already begun (38, 39). Adult bone is a dynamic tissue that 
requires constant remodeling to maintain structural integrity 
and fulfill its metabolic roles. In addition to hormonal signals 
and mechanical stimuli, paracrine effects of local mediators, 
including tissue growth factors, cytokines, and bone matrix 
proteins are important for physiological and pathological bone 
FigUre 7 | Role of PTX3 and FGF2 during in vitro differentiation of bone marrow cells from ptx3+/+ female mice. Bone marrow cells were extracted from ptx3+/+ 
female mice (10–12 weeks of age) and plated in OCL cultures (in the presence of RANKL and M-CSF) or OBL cultures (in the presence of AA and b-GP). Cells from 
two to three mice were pooled and three to four wells were done for each time point. (a) Expression of osteoblast-specific (Osx, ALP, OC) and osteoclast-specific 
(cFms, RANK, CalcR) genes were assessed during bone cell differentiation in parallel with the expression of PTX3 by qPCR. Mean ± SD from four independent 
experiments is reported. (B) Representative microphotographs of osteoblasts differentiated in vitro from bone marrow of ptx3+/+ female mice on B6 background, 
cytochemically stained for ALP. Osteoblast differentiation was evaluated by measurement of ALP+ surface area per well and expression of osteoblast-specific genes 
(Osx, Col1, BSP). Total colony surface was assessed by methylene blue staining. OBL cultures were treated with PTX3 (50 nM) or/and FGF2 (0.5 nM) in addition to 
AA and β-GP. (c) Osteoblast differentiation was evaluated by measurement of surface area covered by ALP+ osteoblast after treatment with either full-length PTX3, 
its N- or C-terminal domain (all used at 50 nM) in addition to FGF2 (0.25 nM or 0.5 nM). The experiments were repeated three times (n = 6–8 wells per group). 
Values are presented as mean ± SD; statistically significant difference between corresponding FGF2-treated groups is marked on plots (*p < 0.05; ANOVA with 
Student–Newman–Keuls post hoc test). (D) Expression of osteoblast-specific genes (Osx, Col1, BSP) in the presence of PTX3 (50 nM), FGF2 (0.25 nM), or a 
combination of PTX3 and FGF2. AA, ascorbic acid; ANOVA, analysis of variance; ALP, alkaline phosphatase; BSP, bone sialoprotein; CalcR, calcitonin receptor; 
cFms, colony-stimulating factor 1 receptor; Col1, α2-chain of type I collagen; OBL, osteoblast; OC, osteocalcin; OCL, osteoclast; Osx, osterix; PTX3, pentraxin 3; 
RANK, receptor activator of nuclear factor-κB.
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turnover (15). The trabecular bone is particularly susceptible to 
modulatory signals and may undergo a negative bone balance in 
the adult organism due to high metabolic rate and great surface 
area-to-volume ratio (21, 38, 40, 41). The presence of lower bone 
mass in the spine of ptx3−/− mice, which in small quadrupeds is 
loaded by much lower forces compared to the femur, suggests 
FigUre 8 | Dissection of osteoprogenitor subpopulations within the fractured areas at early postfracture days in ptx3+/+ female mice. A stabilized closed transversal 
mid-tibial fracture model was applied in female ptx3+/+ mice (14–16 weeks of age). Callus tissue was assessed at 2 (FRd2) and 6 (FRd6) days postfracture by 
immunohistochemistry, flow cytometry, and qPCR. (a) Expression of PTX3, FGF2, osterix, and Runx2 was analyzed by immunohistochemistry on serial sections in 
unfractured tibial periosteal layer (UNFR) and mid-tibial fracture areas (FRd2 and FRd6) from ptx3+/+ female mice. Control stain (not shown) was performed using the 
secondary antibody only (size bar: 100 µm). Low-magnification images (far left panel, hematoxylin stained) is presented to show specimen orientation—
intramedullary compartment comprising bone marrow (BM), bone cortex (BC), and, when applicable, fracture line (FL) and periosteal layer with callus tissue (P/C). 
Rectangles indicate area of interest shown at high magnification (size bar: 100 µm). Arrowheads indicate corresponding (positive) area on serial sections. (B) Flow 
cytometric analysis of PTX3+-positive subset within non-hematopoietic/non-endothelial (CD45−Ter119−CD31−) population of cells in unfractured tibial periosteal layer 
(UNFR), periosteal layer of bones with inserted pin (PIN), and fractured areas involving periosteal reaction and callus tissue (FRd2 and FRd6). (c) Flow cytometric 
analysis of osteoprogenitor subsets expressing αSma, CD105, CD51, CD140b, or Sca-1 marker within PTX3+ population [shown in (B)] for female ptx3+/+ mice 
(n = 6–8 mice per group). (D) qPCR analysis of PTX3 and FGF2 gene expression in non-hematopoietic/non-endothelial (CD45−Ter119−CD31−) compartment of cells 
extracted from unfractured tibial periosteal layer (UNFR), periosteal layer of bones with inserted pin (PIN), and mid-tibial fracture areas (FRd2 and FRd6) of female 
ptx3+/+ mice (n = 3–4 per group).
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that PTX3 is required for bone homeostasis not only in weight 
bearing, rapidly remodeled bones, but also in the axial skeleton.
Bone matrix incorporates a large number of growth factors, 
including insulin-like growth factors, transforming growth 
factor-β, BMPs, platelet-derived growth factor, and parathyroid 
hormone-related protein and FGFs, which play a role in the 
physiologic bone development and in the remodeling associated 
with skeletal repair. Matrix proteins mostly produced by the bone 
cells themselves, such as Col1, ALP, osteonectin, fibronectin, and 
OC, may act as growth factor modulators (16). They participate in 
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the regulation of proliferation, migration, and differentiation of 
osteoblastic cells, especially during the resorption phase of bone 
remodeling when osteoclasts degrade bone matrix, releasing 
the incorporated proteins. Moreover, a number of inflammatory 
mediators including cytokines, chemokines, prostaglandins, and 
leukotrienes are produced by bone and immune cells and, through 
autocrine and paracrine loops, regulate bone cell functions (13, 22). 
However, these inflammatory mediators have been mostly studied 
in the context of pathological inflammation (i.e., arthritis, peri-
odontitis, osteomyelitis), whereas our study determined the role 
of PTX3 in physiological bone remodeling and repair. We found 
that PTX3 is expressed by differentiating osteoblasts in vitro and 
matrix-embedded osteocytes in  vivo and that PTX3-deficient 
mice have significantly lower bone formation and bone repair rate 
than ptx3+/+ controls. Nevertheless, frequency and differentiation 
potential of bone marrow-derived osteoprogenitors in vitro were 
similar in ptx3+/+ and ptx3−/− mice, indicating that an in  situ 
microenvironment is required for the bone-spearing effect of 
PTX3. In addition, culture treatment with exogenous PTX3 did 
not directly affect osteoclast or osteoblast differentiation, similar 
to what observed by Lee et al. (42). This study also showed that 
PTX3 enhanced the RANKL expression in primary mouse calva-
rial osteoblasts and stimulated osteoclastogenesis under high 
TNF-α conditions. Other authors have investigated the role of 
PTX3 in chronic inflammatory diseases with aggravated bone 
resorption, including periodontitis (43–45), arthritis (46–52), 
and tumor-associated inflammation (53, 54), showing increased 
PTX3 levels, especially in areas of inflammation. However, in 
these models, it is difficult, if not impossible, to define whether 
PTX3 is the causal factor of bone loss or it is just a byproduct, 
downstream of pro-inflammatory cytokines that per  se induce 
bone resorption.
As opposed to chronic inflammatory diseases or excessive 
inflammation associated with massive trauma, when the inflam-
matory response has destructive effects on bone tissue, inflamma-
tion plays an immediate beneficial role in promoting regeneration 
after bone fracture or injury (19, 20). A number of inflammatory 
cytokines (TNF-α, IL-1α, IL-1β, and IL-6) are expressed during 
the acute inflammatory phase within a week from fracture, which, 
in cooperation with growth factors and matrix proteins released 
from injured tissues, recruit inflammatory cells, promote angio-
genesis, and guide mesenchymal progenitor cell migration and 
differentiation (19). In our fracture model, the pro-inflammatory 
chemokine CCL2 was particularly useful as an indicator of 
early fracture injury in serum and at the fracture site. Later on, 
remodeling of the mineralized callus by the resorptive action 
of osteoclasts is paralleled by a second peak of inflammatory 
cytokines and matrix proteins. Although the recruited inflam-
matory cells, mainly neutrophils and macrophages, are major 
immediate producers of cytokines and growth factors, in the 
regenerative callus, these mediators are primarily produced by 
bone cells, mainly osteoblasts and chondrocytes (55). Here, we 
showed that PTX3 is expressed in both the early (inflammatory) 
and the late (regenerative) phases of fracture healing. Moreover, 
it is highly induced in non-hematopoietic/non-endothelial popu-
lation of early callus tissue, which is mainly composed of osteopro-
genitor cells expressing mesenchymal/osteoblast lineage markers 
(i.e., αSma, CD51, CD140b). In particular, PTX3 is produced by a 
substantial proportion of CD51+ and αSma+ subsets of osteopro-
genitor cells. Moreover, the proportion of αSma+ subset, which 
label osteoprogenitor cells induced at early postfracture days (26), 
was significantly decreased in ptx3−/− mice. In a model of wound 
healing, Doni et al. also showed that PTX3 was mainly produced 
by non-hematopoietic mesenchymal lineage cells (9). Balanced 
cytokine milieu is crucial for the beneficial effect of acute inflam-
mation on bone regeneration, so alterations in the local concen-
tration of growth factors and inflammatory mediators may have 
significant impacts on the healing process. In mice lacking PTX3, 
callus mineralization is delayed with lower expression of Col1, the 
most abundant osteoblast-specific matrix protein. Despite lack-
ing PTX3, the overall profile of systemic and fracture-associated 
inflammatory indicators (CCL2, IL-1α, IL-6) and inflammatory 
cell subsets (Ly6G, Ly6C, CD11b) in ptx3−/− mice showed no 
significant difference compared to ptx3+/+ mice. To the best of 
our knowledge, there are no other studies investigating the role 
of PTX3 during bone regeneration. However, in the model of 
orthodontic tooth movement, characterized by a rapid bone 
remodeling, PTX3, together with other inflammatory mediators, 
was significantly overexpressed throughout the periodontal liga-
ment of the tension zone (56). Other in vivo studies have dem-
onstrated that mice lacking pro-inflammatory cytokines, such 
as IL-6 or TNF-α, or treated with anti-inflammatory drugs, such 
as cyclooxygenase-2 inhibitors, have disturbed bone formation 
and delayed fracture healing (19, 20, 22). Osteoblasts taken from 
human patients with fracture non-unions have abnormal expres-
sion of genes associated with inflammatory response, suggesting 
that inflammatory mediators are critical for bone healing (57).
Bone remodeling and regeneration relies on tight spatiotem-
poral interactions between growth factors and extracellular 
matrix molecules, which, in an autocrine and paracrine manner, 
promote osteoblast development and differentiation. Our results 
and previous studies showed that human and animal stromal/
osteoblast lineage cells express PTX3 (9, 26, 58, 59). Moreover, 
a recent study by Scimeca et al. indicated importance of PTX3 
for human osteoblast differentiation and showed reduced PTX3 
expression in osteoblasts from osteoporotic patients (60). The 
multifunctional properties of PTX3 are based on its capacity 
to interact with several ligands, including complement compo-
nents, adhesion molecules, growth factors, and matrix compo-
nents (9, 25). In particular, PTX3 binds with high affinity to 
FGF2 (34, 35) and to other members of the FGF family (28, 61) 
via the N-terminal domain and prevents FGF2 from interacting 
with its receptor. The FGF family comprises 22 members, highly 
conserved in evolution (62), exerting various biological activi-
ties both in vivo and in vitro, including roles in angiogenesis, 
mitogenesis, cellular differentiation, cell migration, and tissue 
injury repair. In addition, FGF2 is expressed during the early 
stages of bone formation and is abundantly accumulated in 
bone matrix, participating to osteoblastogenesis and skeletal 
remodeling (63–65). Therefore, we propose that PTX3 might 
exert a bone regulatory effect in repair and remodeling through 
the interaction with locally produced FGF2. At early stages fol-
lowing fracture, non-hematopoietic/non-endothelial cells com-
prising the osteoprogenitor population showed concomitant 
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induction in PTX3 and FGF2 gene expression. The FGF2 protein 
was detected by immunohistochemistry in close proximity to 
the fracture gap, overlapping with the areas of PTX3 staining 
and osteoprogenitor cells expressing Osx and Runx2. FGF2 is 
a key mitogen able to expand the pool of various bone cells, 
including osteoprogenitors. However, its effects in the later 
stages of matrix maturation and mineralization are controver-
sial, with both positive and negative impacts described (66, 67). 
Genetic studies in animals and etiology of human skeletal dys-
plasias showed that FGF2 overexpression as well as mutation of 
FGF2 or the corresponding receptors cause bone abnormalities 
(65, 68). Similar to that described by Kalajzic et al. (69), in our 
in  vitro conditions, FGF2 blocked osteoblast differentiation 
from bone marrow stromal cells, whereas PTX3 (and the PTX3 
N-terminal domain that contains the FGF2-binding sites) 
was able to reverse the inhibitory effect of FGF2. Similarly, 
by sequestering FGF2, PTX3 can inhibit FGF2-dependent 
endothelial cell proliferation in vitro and angiogenesis in vivo 
(33, 35). Several extracellular matrix molecules, besides PTX3, 
are able to trap FGF2 in the extracellular environment (such 
as thrombospondin-1 and cleaved syndecan) and modulate its 
effects during processes such as inflammation, wound healing, 
atherosclerosis, and neoplasia (70, 71).
In conclusion, we observed that PTX3-deficient mice have 
impaired bone formation during physiological remodeling as 
well as regeneration following fracture injury. In particular, PTX3 
is important for adequate osteoblast differentiation and proper 
matrix mineralization, and this effect is achieved, at least in part, 
by sequestering FGF2 in the extracellular matrix of newly remod-
eled bone. We propose that the role of PTX3 in the regulation of 
bone remodeling is a part of its general biological function in the 
orchestration of tissue repair.
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